ReviewBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2022
Impact of Obesity on Response to Biologic Therapies in Patients with Inflammatory Bowel Diseases.
Review in BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Risk Factors for Gallstones in Crohn's Disease: A Systematic Review and Meta-Analysis.Digestive diseases and sciences · 2024Pooled it
- Effectiveness of an app-based walking program for obese patients with inflammatory bowel disease in Korea: a single-blind parallel-group randomized clinical trial.BMC gastroenterology · 2025Trial
- Evaluation of Obesity as an Independent Risk Factor for Colorectal Dysplasia Development in Inflammatory Bowel Disease: A Matched Case-Control Study.Digestive diseases and sciences · 2026Article
- GLP-1 receptor agonists and clinical outcomes in adults with Crohn's disease and obesity: a propensity score-matched real-world cohort study.Scientific reports · 2026Article
- Glucagon-like peptide 1 analogues in patients with inflammatory bowel disease with metabolic disorders: More than weight loss?Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026Article
- Proactive Compared to Reactive Therapeutic Drug Monitoring Is Associated with Less Treatment Failure in Patients with Inflammatory Bowel Disease Treated with Adalimumab.Digestive diseases and sciences · 2026Article
- Obesity: An Overlooked Factor in Inflammatory Bowel Disease.International journal of molecular sciences · 2026Review
- Influence of metabolic syndrome on disease characteristics and activity in inflammatory bowel disease: A retrospective cohort study.Medicine · 2026Article
- Precision Medicine in Inflammatory Bowel Disease: The Emerging Role of Metabolic Dysfunction.Journal of personalized medicine · 2026Review
- The obesity-inflammation axis in psoriatic disease: mechanisms and therapeutic strategies.Nature reviews. Rheumatology · 2026Review
- The Impact of Obesity on Airway Inflammation, Lung Function and Biologic Treatment in Asthma: A Narrative Review.Journal of inflammation research · 2026Review
- Cardiovascular risk in inflammatory bowel disease: focus on lipids and visceral adipose tissue.Frontiers in endocrinology · 2026Review
- THE IMPACT OF OBESITY ON THE CLINICAL COURSE OF INFLAMMATORY BOWEL DISEASE.Arquivos de gastroenterologia · 2026Observational
- Glucagon like peptide 1 receptor agonists in patients with inflammatory bowel disease: safety, clinical effectiveness and anti-inflammatory mechanisms.Frontiers in gastroenterology (Lausanne, Switzerland) · 2026Review
- Development and validation of a predictive nomogram for response to biologics and targeted therapy in Crohn's disease: a retrospective cohort study.Frontiers in immunology · 2026Article
- The prevalence and potential associations of anti-drug antibodies against adalimumab in patients with non-infectious uveitis: a cross-sectional study.Journal of ophthalmic inflammation and infection · 2025Article
- Glucagon-like peptide-1 (GLP-1) receptor agonists in inflammatory bowel disease: mechanisms, clinical implications, and therapeutic potential.Journal of Crohn's & colitis · 2025Review
- Impact ofJournal of clinical medicine · 2025Article
- Use of Glucagon-Like Peptide-1 (GLP-1) Agonists in Modulating Preexisting Dermatologic Disease: A Systematic Review.Cureus · 2025Review
- Longitudinal computed tomography-based delta-radiomics of visceral adipose tissue predicts infliximab secondary loss of response in Crohn's disease patients.World journal of gastroenterology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Approximately 20-40% of patients with inflammatory bowel disease (IBD) are obese. Obesity is associated with inferior outcomes in patients with IBD, with lower rates of achieving remission, poor quality of life, and higher burden of unplanned healthcare utilization. Multiple cohort studies in patients with immune-mediated inflammatory diseases, including IBD, treated with biologic agents like tumor necrosis factor-α antagonists have suggested that obesity is associated with inferior response to biologic therapy. This may be related to the negative impact of obesity on the pharmacokinetics of biologic agents. Pharmacokinetic studies of multiple biologic agents have demonstrated that high body weight is associated with more rapid clearance and a higher volume of distribution of biologic agents, which leads to low trough concentrations. Randomized trials in patients with psoriasis and psoriatic arthritis treated with biologic agents suggest that diet- or lifestyle-induced weight loss is associated with improved response to therapy. This provides an opportunity to explore intentional weight loss as adjunctive therapy in obese patients with IBD. However, diet and lifestyle interventions for weight loss are hard to implement in patients with IBD; hence, long-term therapy with weight-loss agents (such as with phentermine-topiramate, naltrexone-bupropion) is attractive as adjunctive therapy in obese patients with IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.